Repligen Corporation

Valuation Analysis

About the Company

Repligen Corporation en bref

Repligen Corporation (RGEN) is currently trading at 115,21 € with a market capitalization of 6,5 Md €. The trailing P/E ratio stands at 145.08x, with a forward P/E of 51.86x. The 52-week range spans from 88,13 € to 153,39 €; the current price is 24.9% below the yearly high. Year-over-year revenue growth stands at +14.8%. The net profit margin stands at 6.73%.

💰 Dividende

Repligen Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

19 analystes évaluent Repligen Corporation (RGEN) au consensus : None. L'objectif de cours moyen est de 153,69 €, soit un potentiel de +33.39% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 123,92 € à 191,99 €.

Repligen Corporation : la thèse d'investissement en détail

Repligen Corporation (RGEN) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 14.8% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 47.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

Le scénario baissier

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 10.6% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 54.62x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 51.86x is meaningfully below the trailing 145.08x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 33.39% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to market-like volatility, elevated short interest (10.6%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Repligen Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.